Abstract

Triclosan (TCS), a high-production-volume chemical used as a bactericide in personal care products, is a priority pollutant of growing concern to human and environmental health. TCS is capable of altering the activity of type 1 ryanodine receptor (RyR1), but its potential to influence physiological excitation-contraction coupling (ECC) and muscle function has not been investigated. Here, we report that TCS impairs ECC of both cardiac and skeletal muscle in vitro and in vivo. TCS acutely depresses hemodynamics and grip strength in mice at doses ≥12.5 mg/kg i.p., and a concentration ≥0.52 μM in water compromises swimming performance in larval fathead minnow. In isolated ventricular cardiomyocytes, skeletal myotubes, and adult flexor digitorum brevis fibers TCS depresses electrically evoked ECC within ∼10-20 min. In myotubes, nanomolar to low micromolar TCS initially potentiates electrically evoked Ca(2+) transients followed by complete failure of ECC, independent of Ca(2+) store depletion or block of RyR1 channels. TCS also completely blocks excitation-coupled Ca(2+) entry. Voltage clamp experiments showed that TCS partially inhibits L-type Ca(2+) currents of cardiac and skeletal muscle, and [(3)H]PN200 binding to skeletal membranes is noncompetitively inhibited by TCS in the same concentration range that enhances [(3)H]ryanodine binding. TCS potently impairs orthograde and retrograde signaling between L-type Ca(2+) and RyR channels in skeletal muscle, and L-type Ca(2+) entry in cardiac muscle, revealing a mechanism by which TCS weakens cardiac and skeletal muscle contractility in a manner that may negatively impact muscle health, especially in susceptible populations.

Highlights

  • IntroductionTCS is capable of altering the activity of type 1 ryanodine receptor (RyR1), but its potential to influence physiological excitation–contraction coupling (ECC) and muscle function has not been investigated

  • We report that TCS is capable of disrupting excitation–contraction coupling (ECC) in both cardiac and skeletal muscle, resulting in impaired grip strength and hemodynamics, and mobility in a model fish species

  • Our present findings identify a potential for TCS to impair physiological muscle functions in vivo and identify proteins essential for ECC as targets, namely Cav1.1, Cav1.2, and RyR channels

Read more

Summary

Introduction

TCS is capable of altering the activity of type 1 ryanodine receptor (RyR1), but its potential to influence physiological excitation–contraction coupling (ECC) and muscle function has not been investigated. We report that TCS impairs ECC of both cardiac and skeletal muscle in vitro and in vivo. Considering that RyRs are intracellular channels that mediate the release of Ca2+ from the sarcoplasmic reticulum (SR), necessary for excitation–contraction coupling (ECC) in skeletal and cardiac muscle, alteration in ECC by TCS may promote acute or long-term impacts on muscle health in human populations and environmentally sensitive species. Considering the critical role of RyR channels in muscle physiology and pathophysiology, we deemed it necessary to investigate whether TCS has the potential of impairing ECC of cardiac and skeletal muscle in vivo and in vitro to better assess the potential risks associated with its pervasive use

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.